Neurological complications of cancer immunotherapy

Immunotherapy has emerged as a powerful therapeutic approach in many areas of clinical oncology and hematology. The approval ipilimumab, monoclonal antibody targeting the immune cell receptor CTLA-4, marked beginning era checkpoint inhibitors. In meantime, numerous antibodies PD-1 pathway have expanded class clinically approved Furthermore, novel directed against other checkpoints are currently evaluation. More recently, bispecific antibodies, which link T cells directly to tumor well adoptive transfer with engineered express chimeric antigen receptor, been certain indications. Neurological complications associated use these immunotherapeutic concepts recognized more frequently. Immune inhibitors may cause various neurological deficits mainly by alterations peripheral nervous system's integrity. These include radiculopathies, neuropathies, myopathies myasthenic syndromes. Side effects involving central system less frequent but result severe symptoms syndromes.The administration (CAR) is subject rigorous patient selection their frequently including encephalopathy seizures, require immediate action appropriate measures.Close monitoring for key early recognition immunotherapy-related side effects. Comprehensive diagnostic work-up adequate measures essential avoid further deterioration residual deficits.